A novel selective peroxisome proliferator-activated receptor α agonist, 2-methyl-c-5-[4-[5-methyl-2-(4-methylphenyl)-4-oxazolyl]butyl]-1, 3-dioxane-r-2-carboxylic acid (NS-220), potently decreases plasma triglyceride and glucose levels and modifies lipoprotein profiles in KK-Ay mice

Journal of Pharmacology and Experimental Therapeutics

Volumn 309, Issue 3, 2004, Pages 970-977

  Kuwabara, Kenji ^a   Murakami, Kohji ^a   Todo, Makoto ^a   Aoki, Tomiyoshi ^a   Asaki, Tetsuo ^a   Murai, Masatoshi ^a   Yano, Junichi ^a  

^a NIPPON SHINYAKU CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYL C 5 [4 [5 METHYL 2 (4 METHYLPHENYL) 4 OXAZOLYL]BUTYL] 1,3 DIOXANE 2 CARBOXYLIC ACID; BEZAFIBRATE; FENOFIBRIC ACID; NS 220; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PIOGLITAZONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; GENETIC ANALYSIS; GLUCOSE BLOOD LEVEL; HYPERLIPIDEMIA; LIGAND BINDING; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; REPORTER GENE; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; ANTILIPEMIC AGENTS; BINDING SITES; BLOOD GLUCOSE; CELLS, CULTURED; DIOXANES; HUMANS; HYPOGLYCEMIC AGENTS; LIPOPROTEINS; MALE; MICE; OXAZOLES; PROCETOFEN; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRANSCRIPTION FACTORS; TRIGLYCERIDES;

EID: 2442712662     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.103.064659     Document Type: Article

References (37)

1. Barbier O, Torra P, Duguay Y, Blanquart C, Fruchart J-C, Glineur C, and Staels B (2002) Pleiotropic action of peroxisome proliferator-activated receptors in lipid metabolism and atherogenesis. Arterioscler Thromb Vasc Biol 22:717-726.
2. Berger J and Moller DE (2002) The mechanisms of action of PPARs. Annu Rev Med 53:409-435.
3. Brown PJ, Stuart W, Hurley KP, Lewis MC, Winegar DA, Wilson JG, Wilkison WO, Ittoop OR, and Willson TM (2001) Identification of a subtype selective human PPARα agonist through parallel-array synthesis. Bioorg Med Chem Lett 11:1225-1227.
4. Brown PJ, Winegar DA, Plunket KD, Moore LB, Lewis MC, Wilson JG, Sundseth SS, Koble CS, Wu Z, Chapman JM, et al. (1999) A ureido-thioisobutyric acid (GW9578) is a subtype-selective PPARα agonist with potent lipid-lowering activity. J Med Chem 42:3785-3788.
5. Berthou L, Duverger N, Emmanuel F, Langouët S, Auwerx J, Guillouzo A, Fruchart J-C, Rubin E, Denèfle P, Staels B, et al. (1996) Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice. J Clin Investig 97:2408-2416.
6. Cattley RC, DeLuca J, Elcombe C, Fenner-Crisp P, Lake BG, Marsman DS, Pastoor TA, Popp JA, Robinson DE, Schwetz B, et al. (1998) Do peroxisome proliferating compounds pose a heaptocarcinogenic hazard to humans? Regul Toxicol Pharmacol 27:47-60.
7. Cayen MN (1985) Disposition, metabolism and pharmacokineties of antihyperlipidemic agents in laboratory animals and man. Pharmacol Ther 29:157-204.
8. Corton JC, Anderson SP, and Stauber A (2000) Central role of peroxisome proliferator-activated receptors in the actions of peroxisome proliferators. Annu Rev Pharmacol Toxicol 40:491-518.
9. Cronet P, Petersen JFW, Folmer R, Blomberg N, Sjöblom K, Karlsson U, Lindstedt E-L, and Bamberg K (2001) Structure of the PPARα and -γ ligand binding domain in complex with AZ 242; Ligand selectivity and agonist activation in the PPAR family. Structure 9:699-706.
10. 4 pathway to inflammation control. Nature (Lond) 384:39-43.
11. Diabetes Atherosclerosis Intervention Study Investigators (2001) Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 357:905-910.
12. Fujita T, Sugiyama Y, Taketomi S, Sohda T, Kawamatsu Y, Iwatsuka H, and Suzuoki Z (1983) Reduction of insulin resistance in obese and/or diabetic animals by 5-[4-(l-methylcyclohexylmethoxy)benzy]]-thiazolidine-2, 4-dione (ADD-3878, U-63,287, ciglitazone), a new antidiabetic agent. Diabetes 32:804-810.
13. Hertz R and Bar-Tana J (1998) Peroxisome proliferator-activated receptor (PPAR) alpha activation and its consequences in humans. Toxicol Lett 102-103:85-90.
14. Holden PR and Tugwood JD (1999) Peroxisome proliferator-activated alpha: role in rodent liver cancer and species differences. J Mol Endocrinol 22:1-8.
15. Kersten S, Desvergne B, and Wahli W (2000) Roles of PPARs in health and disease. Nature (Lond) 405:421-424.
16. Kliewer SA, Umesono K, Noonan DJ, Heyman RA, and Evans RM (1992) Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature (Lond) 358:771-774.
17. Lambe KG, Woodyatt NJ, Macdonald N, Chevalier S, and Roberts RA (1999) Species differences in sequence and activity of the peroxisome proliferator response element (PPRE) within the acyl CoA oxidase gene promoter. Toxicol Lett 110:119-127.
18. Lee SS-T, Pineau T, Drago J, Lee EJ, Owens JW, Kroetz DL, Fernadez-Salguero PM, Westphal H, and Gonzalez FJ (1995) Targeted disruption of the α isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol Cell Biol 15:3012-3022.
19. Leibowitz MD, Fiévet C, Hennuyer N, Peinado-Onsurbe J, Duez H, Berger J, Cullian CA, Sparrow CP, Baffic J, Berger GD, et al. (2000) Activation of PPARδ alters lipid metabolism in db/db mice. FEBS Lett 473:333-336.
20. Miyachi H, Nomura M, Tanase T, Takahashi Y, Ide T, Tsunoda M, Murakami K, and Awano K (2002) Design, synthesis and evaluation of substituted phenylpropanoic acid derivatives as peroxisome proliferator-activated receptor (PPAR) activators: novel human PPARα-selective activators. Bioorg Med Chem Lett 12:77-80.
21. Mogi M, Abe S, and Hayashi T (1995) Studies on the metabolic fate of fenofibrate (1): absorption, distribution and excretion after the single and repeated administration to rats. Jpn Pharmacol Ther 23 (Suppl 4):S1117-S1131.
22. Murakami K, Tobe K, Ide T, Mochizuki T, Ohashi M, Akanuma Y, Yazaki Y, and Kadowaki T (1998) A novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor-α (PPAR-α) and PPAR-γ effect of PPAR-α activation on abnormal lipid metabolism in liver of Zucker fatty rats. Diabetes 47:1841-1847.
23. Oliver Jr WR, Shenk JL, Snaith MR, Russell CS, Plunket KD, Bodkin NL, Lewis MC, Winegar DA, Sznaidman ML, Lambert MH, et al. (2001) A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport. Proc Natl Acad Sci USA 98:5306-5311.
24. Palmer CN, Hsu M-H, Griffin KJ, Raucy JL, and Johnson EF (1998) Peroxisome proliferator activated receptor-α expression in human liver. Mol Pharmacol 53:14-22.
25. Rubins HB, Davenport J, Babikian V, Brass LM, Collins D, Wexler L, Wagner S, Papademetriou V, Rutan G, and Robins SJ, for the VA-HIT Study Group (2001) Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: The Veterans Affairs HDL Intervention Trial (VA-HIT). Circulation 103:2828-2833.
26. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E, Schaefer EJ, Schectman G, Wilt TJ, and Wittes J, for the Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group (1999) Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 341:410-418.
27. Schoonjans K, Peinado-Onsurbe J, Lefebvre A, Heyman R, Briggs M, Deeb S, Staels B, and Auwerx J (1996) PPARα and PPARγ activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J 15:5336-5348.
28. Seedorf U and Assmann G (2001) The role of PPARα in obesity. Nutr Metab Cardiovasc Dis 11:189-194.
29. Staels B, Vu-Dac N, Kosykh V, Saladin R, Fruchart J-C, Dallongeville J, and Auwerx J (1995) Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase: a potential mechanism for the hypolipidemic action of fibrates. J Clin Investig 95:705-712.
30. Tanne D, Kore-Morag N, Graff E and Goldbourt U, for the BIP Study Group (2001) Blood lipids and first-ever ischemic stroke/transient ischemic attack in the bezafibrate infarction prevention (BIP) registry: high triglycerides constitute an independent risk factor. Circulation 104:2892-2897.
31. The BIP Study Group (2000) Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the bezafibrate infarction prevention (BIP) study. Circulation 102:21-27.
32. Thomas J, Bramlett KS, Montrose C, Foxworthy P, Eacho PI, McCann D, Cao G, Kiefer A, McCowan J, Yu K, et al. (2003) A chemical switch regulates fibrate specificity for peroxisome proliferator-activated receptor α (PPARα) versus liver X receptor. J Biol Chem 278:2403-2410.
33. Torra IP, Gervois P, and Staels B (1999) Peroxisome proliferator-activated receptor alpha in metabolic disease, inflammation, atherosclerosis and aging. Curr Opin Lipidol 10:151-159.
34. Vu-Dac N, Gervois P, Jakel H, Nowak M, Baugé E, Dehondt H, Staels B, Pennacchio LA, Rubin EM, Fruchart-Najib J, et al. (2003) Apolipoprotein A5, a crucial determinant of plasma triglyceride levels, is highly responsive to peroxisome proliferator-activated receptor α activators. J Biol Chem 278:17982-17985.
35. Willson TM, Brown PJ, Sternbach DD, and Henke BR (2000) The PPARs: from orphan receptors to drug discovery. J Med Chem 43:527-550.
36. Xu HE, Lambert MH, Montana VG, Parks DJ, Blanchard SG, Brown PJ, Sternbach DD, Lehmann JM, Wisely GB, Willson TM, et al. (1999) Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. Mol Cell 3:397-403.
37. Xu Y, Mayhugh D, Saeed A, Wang X, Thompson RC, Dominianni SJ, Kauffman RF, Singh J, Bean JS, Bensch WR, et al. (2003) Design and synthesis of a potent and selective triazalone-based peroxisome proliferator-activated receptor α agonist. J Med Chem 46:5121-5124.